Enanta Pharmaceuticals Inc
ENTA
Get informed when a big investor buys or sells
+ FollowMarket Cap$382.67M
Close$
$-7.91
158.8% downside
Current Fair Value
158.8% downsideOvervalued by 158.8% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $382.67 Million |
|---|---|
| Enterprise Value | $404.91 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-3.84 |
| Beta | 0.93 |
| Outstanding Shares | 29,090,000 |
Return
| Return on Equity | -62.56% |
|---|---|
| Return on Assets | -21.30% |
| Return on Invested Capital | -22.04% |
Valuation & Multiples
| P/E Ratio | -5.46 |
|---|---|
| PEG | -80 |
| Price to Sales | 6.72 |
| Price to Book Ratio | 4.48 |
| Enterprise Value to Revenue | 6.2 |
| Enterprise Value to EBIT | -7.57 |
| Enterprise Value to Net Income | -7 |
| Total Debt to Enterprise | 0.14 |
| Debt to Equity | 0.55 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 10, 2026
EPS Estimate
$-0.51
Average shareholder expectationRevenue Estimate
$16.76 M
Average shareholder expectationNext Earnings Call
Expected Date
November 16, 2026
EPS Estimate
$-0.64
Average shareholder expectationRevenue Estimate
$16.18 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.0000▼ 38.12% |
|---|---|
| Total Calls | -▼ 100.00% |
| Total Puts | -▼ 100.00% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 19.86%▼ 105.37% |
|---|---|
| Total Invested | $61.88M▼ 81.70% |
| Investors Holding | 39▼ 96.00% |
ESG Score
No data
About Enanta Pharmaceuticals Inc
CEO: Jay Luly